Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Folic acid, also known as vitamin B9, is an important B-vitamin with many vital functions in the human body. It was ...

H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune DiseaseInterim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with ...

FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

Certain antibodies employ unusual tactics to keep germs from attaching to cells in our bodies. Their defensive strategies ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...

Pathogens can create sticky situations. When microbes invade the body to cause an infection, often one of their first lines ...

Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...